Ha J H, Basile A S
Laboratory of Neuroscience, NIDDKD, National Institutes of Health, Bethesda, MD 20892, USA.
Brain Res. 1996 May 13;720(1-2):35-44. doi: 10.1016/0006-8993(96)00104-7.
The effects of 5-2500 microM concentrations of neutral ammonium salts on the binding of ligands to components of the GABAA receptor complex were investigated. [3H]Flunitrazepam binding to the benzodiazepine receptor was enhanced by ammonium (10-500 microM), but not sodium tartrate with EC50 = 98 microM and Emax = 31%. Further increasing ammonium tartrate concentrations (500-2500 microM) decreased [3H]flunitrazepam binding to control levels. The ammonium tartrate-induced increase in [3H]flunitrazepam binding was manifested as a 50% decrease in Kd. Furthermore, GABA increased the potency of ammonium tartrate in enhancing [3H]flunitrazepam binding by 63%. [3H]Ro 15-1788 and [3H]Ro 15-4513 binding to the benzodiazepine receptor was not significantly enhanced by ammonium tartrate (Emax approximately 13%). Ammonium tartrate also increased, then decreased the binding of 500 nM [3H]muscimol to the GABAA receptor (EC50 = 52 microM, Emax = 30%) in a concentration-dependent manner, but had no effect on [3H]SR 95-531 binding (Emax < 16%). The ammonium tartrate-induced alterations in [3H]muscimol binding were demonstrated in saturation assays as the loss of the high affinity binding site and a 27% increase in the Bmax of the low affinity binding site. These results indicate that ammonia biphasically enhances, then returns ligand binding to both the GABA and benzodiazepine receptor components of the GABAA receptor complex to control levels in a barbiturate-like fashion. This suggests that ammonia may enhance GABAergic neurotransmission at concentrations commonly encountered in hepatic failure, an event preceding the suppression of inhibitory neuronal function observed at higher (> 1 mM) ammonia concentrations. This increase in GABAergic neurotransmission is consistent with the clinical picture of lethargy, ataxia and cognitive deficits associated with liver failure and congenital hyperammonemia.
研究了5 - 2500微摩尔浓度的中性铵盐对配体与GABAA受体复合物各组分结合的影响。铵(10 - 500微摩尔)可增强[3H]氟硝西泮与苯二氮䓬受体的结合,但酒石酸钠则无此作用,其半数有效浓度(EC50)为98微摩尔,最大效应(Emax)为31%。进一步增加酒石酸铵浓度(500 - 2500微摩尔)会使[3H]氟硝西泮结合降至对照水平。酒石酸铵诱导的[3H]氟硝西泮结合增加表现为解离常数(Kd)降低50%。此外,γ-氨基丁酸(GABA)可使酒石酸铵增强[3H]氟硝西泮结合的效力提高63%。酒石酸铵对[3H]Ro 15 - 1788和[3H]Ro 15 - 4513与苯二氮䓬受体的结合增强作用不显著(Emax约为13%)。酒石酸铵还以浓度依赖方式先增加后降低500纳摩尔[3H]蝇蕈醇与GABAA受体的结合(EC50 = 52微摩尔,Emax = 30%),但对[3H]SR 95 - 531结合无影响(Emax < 16%)。在饱和实验中,酒石酸铵诱导的[3H]蝇蕈醇结合变化表现为高亲和力结合位点丧失,低亲和力结合位点的最大结合量(Bmax)增加27%。这些结果表明,氨以双相方式先增强,然后使GABAA受体复合物的GABA和苯二氮䓬受体组分的配体结合恢复到对照水平,类似于巴比妥类药物的作用方式。这表明在肝功能衰竭时常见的氨浓度下,氨可能增强GABA能神经传递,而在较高(> 1毫摩尔)氨浓度下观察到的抑制性神经元功能抑制之前就会出现这种情况。这种GABA能神经传递的增加与肝功能衰竭和先天性高氨血症相关的嗜睡、共济失调和认知缺陷的临床表现一致。